Kezar Life Sciences, Inc. (NASDAQ:KZR) Q3 2019 Earnings Conference Call - Final Transcript

Nov 12, 2019 • 08:30 am ET


Kezar Life Sciences, Inc. (NASDAQ:KZR) Q3 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript

Christopher Kirk

in the first half of 2021 from this six-month treatment duration study.

PRESIDIO also open for enrollment. Because of the randomized crossover nature of the study, there'll be no interim analysis from this trial with full readout late in 2021. And finally the MARINA study, also open for enrollment, because of the short duration in the study and again no placebo group in essence aggregate hematologic data provides us the chance to do an interim analysis late in 2020 with full data readout in the second half of 2021.

So, before I turn it back to John, just again thanks to the team at Kezar for the great execution on the MISSION study as well as the PRESIDIO and MARINA study start-ups, to our great collaborators at the sites and to the patients who have agreed to enroll and study. We're really encouraged by these safety, tolerability and efficacy data, and can't wait to be sharing more data around the clinical activity of 616 with you all hopefully in the near future.

And with that, I'll turn it back to John for a few closing remarks.

John Fowler

Thank you so much, Chris. That was an excellent overview of our new patient data and also for reviewing our Phase 2 trial. Everyone, as Chris shared, we're delighted with this Phase 1b work has allowed us to identify active and well-tolerated doses and a promising path forward into these Phase 2 studies. In particular, we're gratified that the data presented today with the two cohorts receiving step-up dosing is showing a dramatically improved tolerability profile with much lower GI tox rate from the initial doses with 616 seen previously.

As discussed, the safety and tolerability profile of KZR-616 is comfortably in line with many other standard of care medicines for severe autoimmune diseases. So in addition to these key learnings around safety and tolerability, we continue to be excited by the broad improvements observed across all disease measures and the physician and patient reported outcomes. Given the safety and efficacy data in aggregate, we're leaving this year's ACR more excited than ever about the potential of our Phase 2 studies. So before we open it up to questions from our analysts, I want to echo Chris and once again thank the team at Kezar, our our dedicated investigators, and most of all the patients who have together made the MISSION study a success today.

Celia Economides

Kevin, can we open the line for Q&A, please. Thank you.